• January 10, 2023

    “We have assured quantities of medicines manufactured at Tchaikapharma High Quality Medicines. Based on current consumption, we maintain a minimum of a 4-month supply. If there is increased demand, we are ready to respond.”

  • December 6, 2022

    Tchaikapharma’s latest medicinal product to receive marketing authorisation from the Bulgarian Drug Agency is Clopasa (colchicine) 0.5 mg tablets – the first gout treatment in the company’s broad portfolio.   Clopasa belongs to the group of medicines with antipathic action. It is used for the treatment of acute attacks of gout, in the condition of […]

  • October 21, 2022

    The newest medicinal product to receive Marketing Authorization from the Medicines Executive Agency is: Semefro 50 mg/850 mg film-coated tablets Semefro 50 mg/1000 mg film-coated tablets   Active ingredients: sitagliptin/metformin hydrochloride   Semefro contains two different medicines called sitagliptin and metformin. – Sitagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) […]

  • October 19, 2022

    The turnover from transactions with Bulgarian shares reached just under BGN 6 million, and two-thirds of it (just over BGN 4 million) was formed by transactions with shares of Tchaikapharma High Quality Medicines. Another 4 companies formed another quarter of the turnover, SOFIX recorded a minimal decrease.   Read the full article here in Bulgarian.

  • October 5, 2022

    Tchaikapharma has launched two new medicinal products on the market, which are already commercially available: Methylprednisolone-Chaikapharma (methylprednisolone) 40 mg powder and solvent for for injection solution TromBai (cilostazol) 100 mg tablets   The distributor of the medicinal products is Commercial League – Global Pharmа Center.